Showing 321 - 340 results of 506 for search '"combination therapy"', query time: 0.07s Refine Results
  1. 321

    Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis by Biqiong Pan, Xiaojun Lai, Jiefang Lu, Xiaoyan Bao, Zengke Fan, Jie Sun

    Published 2025-02-01
    “…ObjectiveThis meta-analysis evaluated pembrolizumab monotherapy and combination therapy’s efficacy and safety in recurrent or advanced endometrial cancer (EC).MethodsWe utilized PubMed, Embase, Cochrane Library, and Web of Science databases to identify clinical trials that were used to search literature from July 2013 to July 2023 to evaluate the efficacy and safety of pembrolizumab in patients with advanced EC. …”
    Get full text
    Article
  2. 322

    The role of polymorphic variants of arginase genes (<i>ARG1, ARG2</i>) involved in beta-2-agonist metabolism in the development and course of asthma by O. N. Savelieva, A. S. Karunas, Yu. Yu. Fedorova, R. R. Murzina, A. N. Savelieva, R. F. Gatiyatullin, E. I. Etkina, E. K. Khusnutdinova

    Published 2020-07-01
    “…In Russians and Tatars receiving glucocorticoid monotherapy or combination therapy, the association of the rs17249437*T allele and rs17249437*TT genotype of the ARG2 gene with a partially controlled and uncontrolled course of asthma was shown.…”
    Get full text
    Article
  3. 323

    Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes by Mazhar Hussain, Asim Elahi, Abid Hussain, Javed Iqbal, Lubna Akhtar, Abdul Majid

    Published 2021-01-01
    “…Group B patients received OADs such as glimepiride, metformin, sitagliptin, gliclazide, and glibenclamide as monotherapy or combination therapy. The changes in SUA level were primary end points while changes in body weight and body mass index (BMI) from baseline to end point were secondary end points. …”
    Get full text
    Article
  4. 324

    The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario by Haris M. Vaid, Ximena Camacho, John T. Granton, Muhammad M. Mamdani, Zhan Yao, Samantha Singh, David N. Juurlink, Tara Gomes

    Published 2016-01-01
    “…Overall mean age was 59.4 years (±20.3 years) and over 77% of cases were women (n=251). Combination therapy was used to treat 22.9% (n=69) of cases, costing an average of $4,569 (SD $1,544) per month. …”
    Get full text
    Article
  5. 325

    Prevention and Reversal of Diabetes by All-Trans Retinoid Acid and Exendin-4 in NOD Mice by Jyuhn-Huarng Juang, Yang-Hau Van, Chien-Hung Kuo, Mei-Yin Lin, Ying-Hsiu Liu, Han-Ying Chang

    Published 2014-01-01
    “…Thus, we hypothesized that ATRA and exendin-4 combination therapy would prevent and reverse autoimmune diabetes. …”
    Get full text
    Article
  6. 326

    An Update on African Trypanocide Pharmaceutics and Resistance. by Keneth Iceland, Kasozi, MacLeod, Ewan Thomas, Ntulume, Ibrahim, Welburn, Susan Christina

    Published 2023
    “…In humans, the development of resistance and adverse side effects against monotherapies has led to the adoption of nifurtimox-eflornithine combination therapy. Current efforts to develop new prodrug combinations of nifurtimox and eflornithine and nitroimidazole fexinidazole as well as benzoxaborole SCYX-7158 (AN5568) for HAT are in progress while little comparable progress has been done for the development of novel therapies to address trypanocide resistance in AAT. …”
    Get full text
    Article
  7. 327

    Radiomics-based biomarker for PD-1 status and prognosis analysis in patients with HCC by Gulizaina Hapaer, Feng Che, Qing Xu, Qian Li, Ailin Liang, Zhou Wang, Jituome Ziluo, Xin Zhang, Yi Wei, Yuan Yuan, Bin Song, Bin Song

    Published 2025-01-01
    “…(Hazard ratio [HR]: 1.61 [1.23-2.1], P&lt;0.001).ConclusionThe proposed model based on radiomic signature helps to evaluate PD-1 status of HCC patients and may be used for evaluating patients most likely to benefit from sorafenib as a potentially combination therapy regimen with immune checkpoint therapies.…”
    Get full text
    Article
  8. 328
  9. 329

    Successful Treatment of Fungal Dermatitis in a Bottlenose Dolphin (<i>Tursiops truncatus</i>) by Takashi Kamio, Honoka Nojo, Rui Kano, Mami Murakami, Yukako Odani, Koji Kanda, Tomoko Mori, Yuichiro Akune, Masanori Kurita, Ayaka Okada, Yasuo Inoshima

    Published 2025-01-01
    “…This is the first report of successful treatment of pheohyphomycosis and fusariomycosis in a bottlenose dolphin using voriconazole and terbinafine combination therapy and surgical resection.…”
    Get full text
    Article
  10. 330

    Clinical Efficacy and Safety of Stem Cell-Based Therapy in Treating Asherman Syndrome: A System Review and Meta-Analysis by Yiming Zhao, Qifan Luo, Xiao Zhang, Yafei Qin, Jingpeng Hao, Dejun Kong, Hongda Wang, Guangming Li, Xiangying Gu, Hao Wang

    Published 2020-01-01
    “…This meta-analysis systematically reviewed and synthesized the outcomes of stem cell-based therapy in treating Asherman syndrome, which suggest that stem cell and hormone combination therapy was safe and more effective in improving menstruation duration, pregnancy outcome, and endometrial thickness. …”
    Get full text
    Article
  11. 331

    CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells by You-Yu Liu, Wei-Lun Huang, Sin-Tian Wang, Hui-Ping Hsu, Tzu-Ching Kao, Wei-Pang Chung, Kung-Chia Young

    Published 2025-02-01
    “…Therefore, seeking for alternative combination therapy needs urgent attentions in PTEN-loss anti-HER2 resistant breast cancer. …”
    Get full text
    Article
  12. 332

    Efficacy and Safety of a Stimulator Using Low-Intensity Pulsed Ultrasound Combined with Transcutaneous Electrical Nerve Stimulation in Patients with Painful Knee Osteoarthritis by Eu-Deum Kim, Yu Hui Won, Sung-Hee Park, Jeon-Hwan Seo, Da-Sol Kim, Myoung-Hwan Ko, Gi-Wook Kim

    Published 2019-01-01
    “…Therefore, further investigation is warranted to determine whether the combination therapy is beneficial. This trial is registered with KCT0003883.…”
    Get full text
    Article
  13. 333

    Ionizing radiation and photodynamic therapy lead to multimodal tumor cell death, synergistic cytotoxicity and immune cell invasion in human bladder cancer organoids by Annabell Reinhold, Annegret Glasow, Sandra Nürnberger, Annett Weimann, Lucie Telemann, Jens-Uwe Stolzenburg, Jochen Neuhaus, Mandy Berndt-Paetz

    Published 2025-02-01
    “…Background: Photodynamic therapy (PDT) and radiotherapy using ionizing radiation (IR) are promising options for organ-preserving treatment of bladder cancer (BCa). A combination therapy (IR+PDT) could be beneficial for BCa treatment. …”
    Get full text
    Article
  14. 334

    From Pioneering Discoveries to Innovative Therapies: A Journey Through the History and Advancements of Nanoparticles in Breast Cancer Treatment by Basingab FS, Alshahrani OA, Alansari IH, Almarghalani NA, Alshelali NH, Alsaiary AH, Alharbi N, Zaher KA

    Published 2025-01-01
    “…This article also discusses the latest advancements in nanoparticle research, including drug delivery systems and combination therapy innovations, while addressing the current technical, biological, and regulatory challenges. …”
    Get full text
    Article
  15. 335

    High and low dose radiotherapy combined with ICIs for MSS colorectal cancer patients with liver metastases: a phase I study (HaRyPOT) by Yuxuan Ding, Yong Feng, Yangfan Ye, Jiayi Shen, Chang Guo, Xia He, Liangjun Zhu, Lijun Wang

    Published 2025-02-01
    “…Plasma cytokines IL-10, IL-17, and INF-α increased after treatment with both drugs.DiscussionIn summary, this is the first clinical trial demonstrating the safety and immunogenic activity of combined high and low dose radiotherapy with ICIs in MSS colorectal cancer liver metastases (CRLMs). The combination therapy stimulated the immune response and altered the tumour microenvironment, warranting further exploration in the future.…”
    Get full text
    Article
  16. 336
  17. 337

    The Combination of Intravenous Immunoglobulin, Dexamethasone, and a High Dose of Mononuclear Cells Transfusion: An Effective Strategy for Decreasing Donor-Specific Antibodies Durin... by Xiaoping Li, Yu Li, Dingsong Zhang, Xiaozhuang Hu, Lin Liu, Zhongtao Yuan, Shiqi Li, Yancheng Dong, Yingnian Chen, Sanbin Wang

    Published 2025-01-01
    “…The 2-year OS, DFS, and NRM were 63.6%, 45.4%, and 18.2%, respectively. Combination therapy with IVIG, dexamethasone, and a high dose of MNCs transfusion, a simple and efficient procedure, was safe and effective for DSA desensitization and peripheral blood stem cell (PBSC) engraftment.…”
    Get full text
    Article
  18. 338

    Efficacy and safety of immune checkpoint inhibitors in elderly patients with advanced non-small cell lung cancer: a systematic review and meta-analysisResearch in context by Jiacheng Yao, Sihan Li, Lu Bai, Jun Chen, Chengbo Ren, Tingting Liu, Jingping Qiu, Jun Dang

    Published 2025-03-01
    “…In real-world studies, the pooled median OS of ICIs were 11.8 months (95% CI: 11.2–12.4); Eastern Cooperative Oncology Group (EOCG) score, histological type, PD-L1 status, with immune-related adverse events (irAEs), and treatment mode were predictive for OS; rates of irAEs and discontinuation were numerically higher for combination therapy vs. monotherapy. Interpretation: ICIs are associated with a significant improvement in OS and PFS compared to chemotherapy in elderly patients with advanced NSCLC. …”
    Get full text
    Article
  19. 339

    Celastrol boosts fluconazole efficacy against vaginal candidiasis: in vitro and in vivo evidence by Fatma Al-zahraa A. Yehia, Hisham A Abbas, Tarek M. Ibrahim, Basem Mansour, Zuhier A. Awan, Mohammed W. Al-Rabia, Wesam H. Abdulaal, Mustafa Adnan Zeyadi, Solomon Z. Okbazghi, Tarek S. Ibrahim, Wael A. H. Hegazy, Salwa E. Gomaa

    Published 2025-01-01
    “…Efflux-mediated azole resistance is a common resistance mechanism in fluconazole (FLZ)-resistant C. albicans. Combination therapy using natural compounds is a potential approach that can restore fluconazole’s antifungal activity in azole-resistant isolates via efflux pump inhibition. …”
    Get full text
    Article
  20. 340